| Samuel T Lawson, MD | |
|
501 Marshall St, Ste. 104, Jackson, MS 39202-1651 | |
| (601) 969-6404 | |
| (601) 973-4541 |
| Full Name | Samuel T Lawson |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 30 Years |
| Location | 501 Marshall St, Jackson, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578582417 | NPI | - | NPPES |
| 00122611 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 14468 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mississippi Baptist Medical Center | Jackson, MS | Hospital |
| Baptist Medical Center-leake | Carthage, MS | Hospital |
| St Dominic-jackson Memorial Hospital | Jackson, MS | Hospital |
| Mississippi Methodist Rehab Ctr | Jackson, MS | Hospital |
| Baptist Medical Center Attala | Kosciusko, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Foundation Of Central Mississippi Inc | 1153216411 | 233 |
News Archive
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration (FDA), the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers.
A new survey says a significant number of women being treated for infertility would choose the sex of their next child if given the option - and those as yet childless would choose baby girls and boys in approximately equal numbers.
The current COVID-19 crisis puts the world to the test, and research and innovation will be key in tackling this enormous challenge.
As a leading provider of market research, MarketResearch.com is pleased to announce the distribution of a new BioInformant Worldwide, L.L.C. report that found a 21-fold increase (2,100%) in the companies involved in the cord blood banking industry in the past 10 years.
› Verified 4 days ago
| Entity Name | Medical Foundation Of Central Mississippi Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992774814 PECOS PAC ID: 1153216411 Enrollment ID: O20040217000380 |
News Archive
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration (FDA), the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers.
A new survey says a significant number of women being treated for infertility would choose the sex of their next child if given the option - and those as yet childless would choose baby girls and boys in approximately equal numbers.
The current COVID-19 crisis puts the world to the test, and research and innovation will be key in tackling this enormous challenge.
As a leading provider of market research, MarketResearch.com is pleased to announce the distribution of a new BioInformant Worldwide, L.L.C. report that found a 21-fold increase (2,100%) in the companies involved in the cord blood banking industry in the past 10 years.
› Verified 4 days ago
| Entity Name | St. Dominic Jackson Memorial |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235173691 PECOS PAC ID: 4385531847 Enrollment ID: O20040301000818 |
News Archive
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration (FDA), the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers.
A new survey says a significant number of women being treated for infertility would choose the sex of their next child if given the option - and those as yet childless would choose baby girls and boys in approximately equal numbers.
The current COVID-19 crisis puts the world to the test, and research and innovation will be key in tackling this enormous challenge.
As a leading provider of market research, MarketResearch.com is pleased to announce the distribution of a new BioInformant Worldwide, L.L.C. report that found a 21-fold increase (2,100%) in the companies involved in the cord blood banking industry in the past 10 years.
› Verified 4 days ago
| Entity Name | Jackson Heart Clinic. P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659318558 PECOS PAC ID: 0547204091 Enrollment ID: O20050615000346 |
News Archive
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration (FDA), the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers.
A new survey says a significant number of women being treated for infertility would choose the sex of their next child if given the option - and those as yet childless would choose baby girls and boys in approximately equal numbers.
The current COVID-19 crisis puts the world to the test, and research and innovation will be key in tackling this enormous challenge.
As a leading provider of market research, MarketResearch.com is pleased to announce the distribution of a new BioInformant Worldwide, L.L.C. report that found a 21-fold increase (2,100%) in the companies involved in the cord blood banking industry in the past 10 years.
› Verified 4 days ago
| Entity Name | Baptist Medical Center - Yazoo, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619918075 PECOS PAC ID: 5799850376 Enrollment ID: O20080815000433 |
News Archive
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration (FDA), the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers.
A new survey says a significant number of women being treated for infertility would choose the sex of their next child if given the option - and those as yet childless would choose baby girls and boys in approximately equal numbers.
The current COVID-19 crisis puts the world to the test, and research and innovation will be key in tackling this enormous challenge.
As a leading provider of market research, MarketResearch.com is pleased to announce the distribution of a new BioInformant Worldwide, L.L.C. report that found a 21-fold increase (2,100%) in the companies involved in the cord blood banking industry in the past 10 years.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Samuel T Lawson, MD 501 Marshall St, Ste. 104, Jackson, MS 39202-1651 Ph: (601) 969-6404 | Samuel T Lawson, MD 501 Marshall St, Ste. 104, Jackson, MS 39202-1651 Ph: (601) 969-6404 |
News Archive
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration (FDA), the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers.
A new survey says a significant number of women being treated for infertility would choose the sex of their next child if given the option - and those as yet childless would choose baby girls and boys in approximately equal numbers.
The current COVID-19 crisis puts the world to the test, and research and innovation will be key in tackling this enormous challenge.
As a leading provider of market research, MarketResearch.com is pleased to announce the distribution of a new BioInformant Worldwide, L.L.C. report that found a 21-fold increase (2,100%) in the companies involved in the cord blood banking industry in the past 10 years.
› Verified 4 days ago
Graves Crawley Stubblefield Jr., M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 406 Briarwood Dr, Jackson, MS 39206 Phone: 601-991-1933 Fax: 601-978-3844 | |
Dr. Rebecca Chick Pace, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 N State St, Suite 500, Jackson, MS 39202 Phone: 601-352-2273 Fax: 601-714-3415 | |
Jewelian Akbar Baig, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 971 Lakeland Dr Ste 356, Jackson, MS 39216 Phone: 601-200-4644 Fax: 601-200-4645 | |
Jo P Deal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 766 Lakeland Dr # A, Jackson, MS 39216 Phone: 601-368-3440 Fax: 601-368-3441 | |
Caryl P. Sumrall, FNP Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2500 North State Street, Department Of Medicine/division Of General Internal Med, Jackson, MS 39216 Phone: 601-984-5660 | |
Meghan Alford Luter, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2500 N State St, Jackson, MS 39216 Phone: 601-984-5532 | |
Tammy H Young, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1227 N State St, Ste 101, Jackson, MS 39202 Phone: 601-355-2485 Fax: 601-353-1463 |